JPH0925230A - 癌患者治療のためのサートラリンの使用 - Google Patents

癌患者治療のためのサートラリンの使用

Info

Publication number
JPH0925230A
JPH0925230A JP8021609A JP2160996A JPH0925230A JP H0925230 A JPH0925230 A JP H0925230A JP 8021609 A JP8021609 A JP 8021609A JP 2160996 A JP2160996 A JP 2160996A JP H0925230 A JPH0925230 A JP H0925230A
Authority
JP
Japan
Prior art keywords
cancer
sertraline
pharmaceutically acceptable
acid
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP8021609A
Other languages
English (en)
Japanese (ja)
Inventor
Pierre Emile Etienne
エミール エチーネ ピエール
Graig Saxton
サックストン クレイグ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Publication of JPH0925230A publication Critical patent/JPH0925230A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP8021609A 1995-01-17 1996-01-16 癌患者治療のためのサートラリンの使用 Pending JPH0925230A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37314895A 1995-01-17 1995-01-17
US08/373,148 1995-01-17

Publications (1)

Publication Number Publication Date
JPH0925230A true JPH0925230A (ja) 1997-01-28

Family

ID=23471181

Family Applications (1)

Application Number Title Priority Date Filing Date
JP8021609A Pending JPH0925230A (ja) 1995-01-17 1996-01-16 癌患者治療のためのサートラリンの使用

Country Status (9)

Country Link
EP (1) EP0727206A2 (2)
JP (1) JPH0925230A (2)
KR (1) KR960028907A (2)
CN (1) CN1134279A (2)
AU (2) AU2265695A (2)
CA (1) CA2167257C (2)
IL (1) IL116733A (2)
WO (1) WO1996022085A1 (2)
ZA (1) ZA96314B (2)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT409084B (de) * 2000-07-13 2002-05-27 Ledochowski Maximilian Dr Antimykotisch wirkendes arzneimittel
GB0202337D0 (en) * 2002-02-01 2002-03-20 Univ Birmingham Cancer treatment
FR2849382A1 (fr) * 2002-12-26 2004-07-02 Urogene Utilisation du gene htr2b pour le traitement du cancer de la prostate
EP1656124A1 (en) * 2003-03-12 2006-05-17 Cerenis Methods and compositions for the treatment of cancer
US20060009506A1 (en) * 2004-07-09 2006-01-12 Odyssey Thera, Inc. Drugs for the treatment of neoplastic disorders
FR2888506A1 (fr) * 2005-07-12 2007-01-19 Cerenis Sa Utilisation de la 4-(3,4-dichloro-phenyl)-1,2,3,4- tetrahydro-naphtalen-1-ylamine pour le traitement du cancer
SG176571A1 (en) * 2009-05-19 2012-01-30 Vivia Biotech Sl Methods for providing personalized medicine tests ex vivo for hematological neoplasms
CN109330998A (zh) * 2018-09-19 2019-02-15 天津科技大学 一种胺盐酸盐化合物的新用途
CN112661657B (zh) * 2021-01-07 2023-07-21 中国人民解放军陆军军医大学 一种舍曲林侧链氨基结构衍生物及其制备方法和应用
CN117017990A (zh) * 2023-08-28 2023-11-10 温州医科大学 厄达替尼联用度洛西汀或舍曲林在制备治疗肿瘤的药物中的应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4596807A (en) * 1985-03-26 1986-06-24 Serotonin Industries Of Charleston Method and compositions for controlling pain, depression and sedation

Also Published As

Publication number Publication date
KR960028907A (ko) 1996-08-17
CN1134279A (zh) 1996-10-30
IL116733A (en) 2000-09-28
EP0727206A2 (en) 1996-08-21
WO1996022085A1 (en) 1996-07-25
IL116733A0 (en) 1996-05-14
EP0727206A3 (2) 1996-08-28
AU2265695A (en) 1996-08-07
CA2167257A1 (en) 1996-07-18
CA2167257C (en) 1999-09-07
AU4202096A (en) 1996-07-25
ZA96314B (en) 1997-07-16

Similar Documents

Publication Publication Date Title
TW541178B (en) Pharmaceutical combination for treatment of psychoses
JPH0925230A (ja) 癌患者治療のためのサートラリンの使用
US5532244A (en) Potentiation of drug response
JP2001520195A (ja) 医薬の増強
JPH0564930B2 (2)
HUE034775T2 (hu) Rákos sejt célzása nanorészecskék alkalmazásával
NZ507981A (en) Combination therapy for treatment of bipolar disorders
CN111386113A (zh) 包含lsz102和阿培利司的药物组合
WO2020023910A1 (en) Methods for treating diseases associated with abnormal acvr1 expression and acvr1 inhibitors for use in the same
US5958429A (en) Potentiation of serotonin response
JP2005538065A (ja) セロトニンファミリーの受容体および血液脳関門に関する免疫調節および細胞過程への影響
EP1626703A2 (en) Dopamine and agonists and antagonists thereof for modulation of suppressive activity of cd4+cd25+ regulatory t cells
US6440988B1 (en) Use of agonists or antagonists of the 5-HT7 receptor to treat disorders of the bladder
JP5681227B2 (ja) メチルフェニデート誘導体を含む治療剤及び医薬組成物
Sommers et al. Oxyphil parathyroid adenomas
TWI302455B (en) Pharmaceutical composition for treating obsessive-compulsive disorder
CA2443012C (fr) Utilisation de derives de pyridoindolone pour la preparation de medicaments
JPH0930959A (ja) 後壁心筋梗塞治療へのサートラリンの使用
US20050070577A1 (en) Compositions containing a serotonin selective reuptake inhibitor and a 5-HT2A receptor antagonist
US20050054688A1 (en) Selective serotonin reuptake inhibitors in the treatment of disease
JP2004123567A (ja) 抗癌剤耐性克服剤
US20030004207A1 (en) Use of compounds which activate a 5-ht receptor to treat urinary incontinence
Gorman et al. Stroke due to atrial myxoma in a young woman with co-existing acoustic neuroma and pituitary adenoma
JPH11228422A (ja) 抗マラリア剤
TW446560B (en) Pharmaceutical compositions for use in inhibiting colon tumors